14 Schoolhouse Road
+1 866 720 3148
Catalent offers the broadest range of services and technologies to transform your molecule into a successful treatment — from specific challenges, tailored solutions or fully-integrated support.
Catalent is the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With more than 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.
Given Catalent’s expertise and capacity, our experts can enter the process at any stage in your product’s lifecycle. That’s why we like you to start thinking about protecting your brand and improving product early in our partnership so we can add value and differentials from the start.
With our broad range of expert services – including analytical, biologics, preformulation, and formulation – we drive faster, more efficient development timelines and produce better products. Our robust GPEx mammalian cell line engineering technology accelerates large molecule drugs from discovery to clinic, and our unique Optiform technology ensures maximum API optimisation. With our deep expertise and our extensive formulation capabilities in oral dose forms, controlled release, inhaled dose forms and softgel technologies, we can solve even the most complex bioavailability, solubility, and permeability challenges.
We are a world leader in drug delivery solutions with a proven track record of helping our customers create better treatments by boosting bioavailability, solubility, and permeability; improving ease and route of administration; and increasing patient compliance. Our unique delivery technologies – including softgel solutions, Liqui-Gels capsules, and Vegicaps capsules, Zydis fast dissolve, controlled release, and inhaled dose forms – improve how products work in and for patients.
As a seamless extension of your supply chain, we have the technology and expertise to offer global, integrated manufacturing and packaging solutions to take your product from design to clinical trial, plant, and pharmacy. We manufacture oral, sterile, and inhaled dose forms, produce biologics for preclinical and clinical studies, and are the recognized leader in biotechnology product packaging.
OmegaZero; EasyBurst; Vegicaps; Graphicaps.
Join our #GeneTherapy experts at the World Vaccine Congress in Washington, DC from April 6 – 9 to learn how our decades of development, analytical & manufacturing expertise can help bring your next #vaccine candidate through clinical trials. https://t.co/ATKnMoFmCe #wvc2020— Catalent Pharma (@CatalentPharma) February 26, 2020
The FDA has approved a new option for the 26 million Americans with asthma that could save money as well as lives: the first stand-alone generic asthma inhaler. @NBCNews medical correspondent Dr. John Torres reports on TODAY. https://t.co/kAhBbOVYjQ @PerrigoCompany— Catalent Pharma (@CatalentPharma) February 26, 2020